NGEN
NASDAQ · Pharmaceuticals
Nervgen Pharma Corp
$3.96
+0.04 (+1.02%)
Open$3.91
Previous Close$3.92
Day High$4.03
Day Low$3.90
52W High$8.49
52W Low$2.57
Volume—
Avg Volume63.6K
Market Cap453.68M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+215.4% upside
Current
$3.96
$3.96
Target
$12.49
$12.49
$8.17
$12.49 avg
$18.41
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 153.26M | 151.64M | 138.95M |
| Net Income | 33.69M | 27.50M | 27.23M |
| Profit Margin | 22.0% | 18.1% | 19.6% |
| EBITDA | 48.41M | 46.31M | 47.02M |
| Free Cash Flow | 29.41M | 26.14M | 25.26M |
| Rev Growth | +15.3% | +9.0% | +25.0% |
| Debt/Equity | 0.51 | 0.65 | 0.45 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |